David John Rabbolini

Dr. David John Rabbolini


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in Critical Care
Verified
Journal Article
Open access
PDF file
LCLucy A. Coupland
Lucy A. Coupland
DRDavid John Rabbolini
David John Rabbolini
JSJonathan G. Schoenecker
Jonathan G. Schoenecker
PCPhilip Crispin
Philip Crispin
JMJennene J. Miller
Jennene J. Miller
AAAnders Aneman
Anders Aneman
Background: Fibrinolysisis is essential for vascular blood flow maintenance and is triggered by endothelial and platelet release of tissue plasminogen activator (t-PA). In certain critical conditions, e.g. sepsis, acute respiratory failure (ARF) and trauma, the fibrinolytic response is reduced and may lead to widespread thrombosis and multi-organ failure. The mechanisms underpinning fibrinolysis resistance include reduced t-PA expression and/or release, reduced t-PA and/or plasmin effect due to elevated inhibitor levels, increased consumption and/or clearance. This study in critically ill patients with fibrinolysis resistance aimed to evaluate the ability of t-PA and plasminogen supplementation to restore fibrinolysis with assessment using point-of-care ClotPro viscoelastic testing (VET). Methods: In prospective, observational studies, whole-blood ClotPro VET evaluation was carried out in 105 critically ill patients. In 32 of 58 patients identified as fibrinolysis-resistant (clot lysis time > 300 s on the TPA-test: tissue factor activated coagulation with t-PA accelerated fibrinolysis), consecutive experimental whole-blood VET was carried out with repeat TPA-tests spiked with additional t-PA and/or plasminogen and the effect on lysis time determined. In an interventional study in a patient with ARF and fibrinolysis resistance, the impact of a 24 h intravenous low-dose alteplase infusion on coagulation and fibrinolysis was prospectively monitored using standard ClotPro VET. Results: Distinct response groups emerged in the ex vivo experimental VET, with increased fibrinolysis observed following supplementation with (i) t-PA only or (ii) plasminogen and t-PA. A baseline TPA-test lysis time of > 1000 s was associated with the latter group. In the interventional study, a gradual reduction (25%) in serial TPA-test lysis times was observed during the 24 h low-dose alteplase infusion. Conclusions: ClotPro viscoelastic testing, the associated TPA-test and the novel experimental assays may be utilised to (i) investigate the potential mechanisms of fibrinolysis resistance, (ii) guide corrective treatment and (iii) monitor in real-time the treatment effect. Such a precision medicine and personalised treatment approach to the management of fibrinolysis resistance has the potential to increase treatment benefit, while minimising adverse events in critically ill patients. Trial registration: VETtiPAT-ARF, a clinical trial evaluating ClotPro-guided t-PA (alteplase) administration in fibrinolysis-resistant patients with ARF, is ongoing (ClinicalTrials.gov NCT05540834; retrospectively registered September 15th 2022).

19 May 2022 in Platelets
Verified
Journal Article
Open access
HVHrushikesh Vyas
Hrushikesh Vyas
AAAhmad Alcheikh
Ahmad Alcheikh
GLGillian Lowe
Gillian Lowe
WSWilliam S Stevenson
William S Stevenson
NMNeil Morgan
Neil Morgan
DRDavid John Rabbolini
David John Rabbolini
ANKRD26 is a highly conserved gene located on chromosome 10p12.1 which has shown to play a role in normal megakaryocyte differentiation. ANKRD26-related thrombocytopenia, or thrombocytopenia 2, is an inherited thrombocytopenia with mild bleeding diathesis resulting from point mutations the 5ʹUTR of the ANKRD26 gene. Point mutations in the 5ʹUTR region have been shown to prevent transcription factor-mediated downregulation of ANKRD26 in normal megakaryocyte differentiation. Patients with ANKRD26-related thrombocytopenia have a predisposition to developing hematological malignancies, with acute myeloid leukemia and myelodysplastic syndrome most commonly described in the literature. We review the clinical features and biological mechanisms of ANKRD26-related thrombocytopenia and summarize known cases in the literature.

16 November 2017 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
KFK. Fixter
K. Fixter
DRDavid John Rabbolini
David John Rabbolini
BVB. Valecha
B. Valecha
MMMarie-Christine Morel-Kopp
Marie-Christine Morel-Kopp
SGS. Gabrielli
S. Gabrielli
CWC. M. Ward
C. M. Ward

1 February 2020 in Pathology
Verified
Journal Article
Closed access
DRDavid John Rabbolini
David John Rabbolini
DCDavid Connor
David Connor
MMMarie-Christine Morel-Kopp
Marie-Christine Morel-Kopp
DDDea Donikian
Dea Donikian
MKMayuko Kondo
Mayuko Kondo
CWChristopher Ward
Christopher Ward

5 June 2017 in Platelets
Verified
Journal Article
Open access
DRDavid John Rabbolini
David John Rabbolini
MMMarie-Christine Morel-Kopp
Marie-Christine Morel-Kopp
CWChristopher M. Ward
Christopher M. Ward
WSWilliam S. Stevenson
William S. Stevenson
(2017). GFI1B variants associated with thrombocytopenia. Platelets: Vol. 28, No. 5, pp. 525-527.

15 June 2021 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
GMGeorge A. Mason
George A. Mason
DRDavid John Rabbolini
David John Rabbolini
Platelet dysfunction, whether hereditary or acquired, may increase an individual's risk of spontaneous, posttraumatic, or postoperative bleeding. Conversely, increased platelet reactivity on antiplatelet agents following vascular (in particular, coronary vascular) intervention may increase the risk of thrombosis and adverse vascular events. The aim of platelet function testing is to identify and characterize platelet dysfunction in these settings to inform bleeding/ thrombosis risk and guide perioperative prophylactic management strategies. A vast array of screening and diagnostic tests is available for this purpose. The successful clinical application of platelet function tests depends on the knowledge of their analytical strengths and limitations and the correct extrapolation of derived results to a particular clinical scenario. This review critically appraises traditional and contemporary platelet function testing focusing on their role in clinical practice.